the present invention refers to recombinant strains of mycobacterium that encode the mutant escherichia coli heat - labile toxin lt this invention also refers to recombinant strains of mycobacterium that encode the a subunit of the mutant escherichia coli heat - labile toxin lt . in particular , this invention refers to strains of mycobacterium that encode the mutant heat - labile toxin lt or a subunit of the escherichia coli heat - labile toxin lt at position 63 . more particularly , this invention refers to strains of mycobacterium that encode the mutant heat - labile toxin lt or a subunit of the escherichia coli heat - labile toxin at position 63 from serine to lysine , respectively rbcg - ltk63 and rbcg - ltak63 . the above mentioned mutations allow the escherichia coli heat - labile toxin lt or the a subunit of the escherichia coli heat - labile toxin lt encoded by mycobacterium to maintain the adjuvant properties of the native lt , yet they lose the adp - ribosyltransferase activity associated with toxicity , thus avoiding toxicity problems in the case of humans or other animals . strains of mycobacterium that encode the heat - labile toxin lt or the a subunit of the escherichia coli heat - labile toxin lt that exhibit other mutations in their sequence that target an equivalent effect , i . e . maintenance of the adjuvant properties of the native lt and reduction or suppression of toxicity , are also involved in this invention . such mutations may include , but are not limited to , positions 72 and 192 . the strains of this invention are obtained from any strain of the genus mycobacterium as carrier for presentation of one or more antigens of different organisms , obtained and cloned in expression vector in mycobacteria and inserted by means genetic manipulation . the recombinant mycobacterium strains of this invention preferably include strains of the mtb complex , mycobacterium tuberculosis , mycobacterium bovis , mycobacterium microtti and mycobacterium africanum or of fast - growing mycobacteria , mycobacterium smegmatis , m . aurum , m . vaccae , etc . the recombinant mycobacterium strains of this invention more preferably include strains of mycobacterium bovis bacillus calmette guerin ( bcg ). the present invention refers to immunogenic compositions involving one or more strains of this invention and one or more within a physiologically acceptable vehicle , excipient , diluent or solvent . the compositions of this invention preferably include strains of mycobacterium bovis bacillus calmette guerin ( bcg ), which encode the mutant heat - labile toxin lt at position 63 from serine to lysine , i . e ., rbcg - ltk63 . alternatively , the compositions of this invention preferably include strains of mycobacterium bovis bacillus calmette guerin ( bcg ), which encode the a subunit of the mutant heat - labile toxin lt at position 63 from serine to lysine , i . e ., rbcg - ltak63 . the compositions of this invention may also involve a mixture of strains of mycobacterium bovis bacillus calmette guerin ( bcg ), which encode the mutant heat - labile toxin lt at position 63 from serine to lysine , i . e ., rbcg - ltk63 and the a subunit of the mutant heat - labile toxin lt at position 63 from serine to lysine , i . e ., rbcg - ltak63 . the immunogenic compositions of this invention may also additionally involve one or more antigens , preferably inactivated toxins . such antigens may be for use in the prevention and / or treatment of tuberculosis or of other diseases caused by different pathogens . the inactivated components of the synergic immunogenic compositions of this invention can be obtained using any method known in the technique , such as chemical procedures , such as treatment with formaldehyde or hydrogen peroxide , or even dna recombination techniques . according to this invention , adjuvants are attenuated or dead molecules , components , macromolecules or microorganisms that potentiate the response to immunizations , reduce the amount of antigen required and direct the type of immune response to be developed , besides sustaining it for a longer period of time , as an immunogen ; it is any material or substance that alters the type , speed , intensity or duration of the immune response . the compositions of this invention can also include excipients , such as bactericides , bacteriostatics , antioxidants , preservatives , buffers , stabilizers , ph adjusters , osmolarity adjusters , antifoaming agents and surfactants ; and residues of antigen inactivation or fractionating agents , growth media components and solvents commonly used in the production of vaccines ; examples of these types of component can be found in the epidemiology and prevention of vaccine - preventable diseases the pink book , 11 th edition , under “ vaccine excipient & amp ; media summary ” ( centers for disease control and prevention . epidemiology and prevention of vaccine - preventable diseases . atkinson w , wolfe s , hamborsky j , mcintyre l , eds . 11th ed . washington , d . c . : public health foundation , 2009 ) incorporated here as a reference . as employed in this invention , the use of the term “ pharmaceutically acceptable ” means an inert nontoxic solid , semisolid liquid excipient , diluent , ancillary formulation of any kind , or simply a sterile aqueous medium , such as saline solution . some examples of the materials that can serve as pharmaceutically acceptable vehicles are sugars , such as lactose , glucose and sucrose , the searches , such as corn starch and potato starch , cellulose and its derivatives , such as sodium carboxymethyl cellulose , ethylcellulose and cellulose acetate , cyclodextrin ; oils , such as peanut oil , cottonseed oil , sunflower oil , sesame oil , olive oil , corn oil and soybean oil ; glycols , such as propylene glycol , poly oils , such as glyceringlycol , sorbitol , mannitol and polyethylene ; esters , such as ethyl laurate , ethyl oleate , agar ; buffering agents , such as aluminum hydroxide and magnesium hydroxide ; alginic acid ; pyrogen - free water ; isotonic saline , ringer &# 39 ; s solution ; buffer solutions of ethyl alcohol and phosphate , as well as other compatible nontoxic substances used in pharmaceutical formulations . a range of routes for administration of the immunotherapy compositions and vaccines described in this invention is available . the particular method selected will depend on the particular active ingredient selected , the necessary dosage for therapeutic efficacy and on the patient to whom the composition is to be administered . the methods of the present invention can generally be practiced using any biologically acceptable means of administration , i . e ., any method that produces effective levels of immune response without causing clinically undesirable adverse effects . such methods of administration include the intradermal , oral , rectal , sublingual , topical , nasal , transdermal or parenteral routes . the term “ parenteral ” includes subcutaneous , intravenous , epidural , irrigation , intramuscular , release or infusion pumps . in this invention particularly , the intradermal , oral , parenteral and nasal routes are preferred for administering the compositions advocated here . for parenteral administration , the active ingredients can be dissolved in a pharmaceutical vehicle and administered as a solution , or emulsion , including micro - and nanoemulsions , or suspension . examples of appropriate vehicles are water , saline , dextrose solutions , fructose solutions or oils of animal , vegetable or synthetic origin . for nasal administration , the active ingredients can be dissolved in a pharmaceutical vehicle and administered as a solution , or emulsion , including micro - and nanoemulsions , or suspension . examples of appropriate vehicles are water and saline solution or solid suspensions , such as spray , lactose , fructose or chitosan flakes . other vehicles can also contain other ingredients , e . g ., preservatives , suspensor agents , solubilizing agents , buffers and alike . the immunogenic compositions of this invention are preferably for intradermal , oral and parenteral administration . the strains and the immunogenic compositions of this invention exhibit an unexpected synergic effect on the immune response against mycobacterium . the recombinant antigens of ltk63 or ltak63 exhibit the unexpected technical effect of inducing an adjuvant effect against the proteins of the actual mycobacterium . as can be seen in the examples below , the strains and the immunogenic compositions of this invention exhibit the unexpected technical effect of producing a more intense anti - tb immune response than vaccines involving traditional bcg . in other words , the addition of an immunogenic domain , such as the nontoxic subunit ltak63 of the e . coli heat - labile toxin , which is known to have no bond with any type of mycobacteria , in a recombinant mycobacterium , in particular bcg , brings about an increase in the protective response against tuberculosis . in particular the strains and the immunogenic compositions of this invention promote a decrease in the bacillary load in the lungs in animal models of tuberculosis . moreover , the strains and the immunogenic compositions of this invention lead to a significant increase in the expression of ifn - γ in relation to the control group , a cytokine considered essential in the response against tuberculosis ; this fact indicates a th1 polarized response . the strains and immunogenic compositions of this invention also lead to a significant increase in tnf - α . since tnf - α is related as a signaler of proinflammatory action , characterizing the acute phase of the inflammatory process triggered by the bacilli , then the vaccines of this invention promote direct activation of the immune system . finally , we can conclude that the strains and the immunogenic compositions of this invention , in combining mycobacteria , in particular bcg , and toxin derivatives of other pathogens , preferably of escherichia coli , generating a recombinant mycobacterial strain , constitute a new vaccine that is more potent and effective than conventional bcg for prophylaxis or immunization against tuberculosis . considering the properties of the recombinant strains of mycobacterium and of the immunogenic compositions of this invention , another aspect of this invention is the use of immunogenic compositions to prevent infections caused by mycobacteria , in particular mycobacterium tuberculosis in animals , more particularly humans . another aspect of this invention is the use of one or more recombinant strains of mycobacterium or of one or more immunogenic compositions of this invention in the production of a vaccine . more particularly , an aspect of this invention is the use of one or more recombinant mycobacterium strain or of one or more immunogenic compositions of this invention in the production of a vaccine for the prevention and / or treatment of tuberculosis and / or infections caused by mycobacteria . yet another aspect of this invention is the methods used to prevent or treat tuberculosis in animals , more particularly humans . to allow a better understanding of this invention and to clearly demonstrate the technical advances obtained , we present below , as examples , the results of the different assays carried out in relation to this invention . in example 1 we describe the obtainment of the vaccines of this invention . the other examples ( 2 to 3 ) serve to illustrate the properties and the use or the vaccine of this invention . these examples are presented merely for illustration and should in no way be considered as limiting the scope and sphere of this invention . a ) preparation of competent bcg stock batch : to prepare stocks of competent bcg , one or more bcg colonies were cultured in middlebrook 7h9 plus tween - 80 liquid medium and supplemented with 10 % albumin dextrose catalase ( mb7h9 / tw / adc ) until the exponential phase . composition of the middlebrook 7h9 medium according to the manufacturer ( difco - ed ) ammonium sulfate , l - glutanic acid , sodium citrate , pyridoxine , biotin , disodium phosphate , mono - potassium phosphate , ferric ammonium citrate , magnesium sulfate , calcium chloride , zinc sulfate and copper sulfate . after this the culture was sedimented by centrifugation at 4000 rpm and washed twice with 10 % glycerol at 4 ° c ., then finally resuspended in 5 % of the original volume , with 10 % glycerol and stored at − 70 ° c . until its transformation by electroporation with pnl12 - ltk63 plasmid or with pnl12 - ltak63 plasmid . b ) construction of the expression vector of the ltk63 gene in recombinant bcg here called pnl12 - ltk63 : the mycobacterial expression vector used for expression of ltk63 in recombinant bcg is called pmip12 and was described by le dantec [ le dantec et al . 2001 j bacteriol . 183 : 2157 - 2164 ]. the ltk63 gene was kindly contributed by dr . rino rappuoli ( novartis ). the expression vector in recombinant bcg of the ltk63 gene was constructed using conventional molecular biology methods . the ltk63 gene was amplified by pcr using the following initiator oligonucleotides : n - terminus containing the pst i restriction site ( underlined ). the pcr product corresponding to the ltk63 gene was generated using the following pcr conditions : 94 ° c . for 4 minutes ; 25 cycles of 94 ° c . for 1 min , 50 ° c . for 1 min and 72 ° c . for 30 s ; and 4 ° c . final . this pcr product was then digested with the restriction enzymes kpn i and pst i and then cloned in the expression vector pmip12 , which was also previously digested with the same enzymes kpn i and pst i , thus generating the expression vector called pmip12 / ltk63 . c ) construction of the expression vector of the ltak63 gene in recombinant bcg here called pln12 - ltak63 : the expression vector in recombinant bcg of the ltak63 gene was constructed using conventional molecular biology methods . the ltak63 gene was amplified by pcr from the ltk63 gene using the following initiator oligonucleotides : n - terminus containing the kpn i restriction site ( underlined ). the pcr product corresponding to the ltak63 gene was generated using following pcr conditions : 94 ° c . for 4 minutes ; 25 cycles of 94 ° c . for 1 min , 50 ° c . for 1 min and 72 ° c . for 30 s ; and 4 ° c . final . this pcr product was then digested with the restriction enzymes bamh i and kpn i and then cloned in the expression vector pmip12 , which was also previously digested with the same enzymes bamh i and kpn i , thus generating the expression vector called plnip / ltak63 . e ) obtainment of the strain of recombinant bcg expressing ltk63 , rbcg - ltk63 to prepare rbcg - ltk63 , a stock aliquot of 50 - 200 μl of competent bcg was mixed with 0 . 1 - 1 μg of pnl12 - ltk63 , in 2 mm electroporation cuvettes and this was submitted to pulsations of 2 . 5 kv , 25 μf and 1000ω , in an electroporation system ( genepulser , biorad , hemel hempstead , uk ). after electroporation , the content of the cuvettes was recovered in 2 ml of medium ( mb7h9 / tw / adc ) without antibiotic and incubated at 37 ° c . for 20 h before being seeded in middlebrook 7h10 ( difco ) solid medium , supplemented with 10 % oleic acid - albumin - dextrose - catalase ( mb7h10 / oadc ) plus kanamycin ( 20 μg / ml ) for selection of the transformants . approximate composition of the middlebrook 7h10 solid medium according to the manufacturer ( difco - bd ): ammonium sulfate , potassium monophosphate , potassium biphosphate , sodium citrate , magnesium sulfate , calcium chloride , zinc sulfate , copper sulfate , l - glutamic acid , ferric ammonium citrate , pyridoxine hydrochloride , biotin , malachite green and agar . the selected rbcg colonies were then transferred to 5 ml of liquid medium of mb7h9 / tw / adc culture with kanamycin ( 20 μg / ml ). e ) obtainment of the strain of recombinant bcg expressing the a subunit ltak63 , rbcg - ltak63 : to prepare rbcg - ltak63 , a stock aliquot of 50 - 200 μl of competent bcg was mixed with 0 . 1 - 1 μg of pln12 - ltak63 , in 2 mm electroporation cuvettes and this was submitted to pulsations of 2 . 5 kv , 25 μf and 1000ω , in an electroporation system ( genepulser , biorad , hemel hempstead , uk ). after electroporation , the content of the cuvettes was recovered in 2 ml of medium ( mb7h9 / tw / adc ) without antibiotic and incubated at 37 ° c . for 20 h before being seeded in middlebrook 7h10 solid medium ( difco ) supplemented with 10 % oleic acid - albumin - dextrose - catalase ( mb7h10 / oadc ) plus kanamycin ( 20 μg / ml ) for selection of the transformants . approximate composition of the middlebrook 7h10 solid medium according to the manufacturer ( difco - bd ): ammonium sulfate , potassium monophosphate , potassium biphosphate , sodium citrate , magnesium sulfate , calcium chloride , zinc sulfate , copper sulfate , l - glutamic acid , ferric ammonium citrate , pyridoxine hydrochloride , biotin , malachite green and agar . the selected rbcg colonies were then transferred to 5 ml of liquid medium of mb7h9 / tw / adc culture with kanamycin ( 20 μg / ml ). g ) preparation of the batches of rbcg - ltk63 and rbcg - ltak63 : next the clones of these two strains were expanded to 50 ml of me7h9 / tw / adc liquid medium or in any medium described for the culture of mycobacteria plus kanamycin ( 20 μg / ml ). after 2 - 3 weeks , when the culture reaches do 600 0 . 6 - 0 . 8 , the samples were centrifuged , washed twice with distilled h 2 o , resuspended in 1 ml of 10 % glycerol and aliguoted at a volume of 50 μl , then stored at − 80 ° c ., for subsequent use in the immunization assays . h ) evaluation of the batches of rbcg - ltk63 and rbcg - ltak63 : the viability of the batches of rbcg - ltk63 and rbcg - ltak63 was assessed by counting the number of colony - forming units ( cpu ). the cfu number was determined as follows : one or more aliquots of the batch frozen at were thawed and several successive dilutions ( 1 × 10 2 , 1 × 10 4 , 1 × 10 5 and 1 × 10 6 ) performed . then the 1 × 10 5 and 1 × 10 6 dilutions were cultured in mb7h10 / oadc medium plus kanamycin ( 20 μg / ml ) and incubated at 37 ° c . after 3 - 4 weeks the number of colonies on the plate is counted . as it was not possible to determine the expression of the ltk63 gene using the classic immunoassay method , the characterization of the ltk63 expression was performed indirectly by confirming the presence of the ltk63 gene in the plasmid inside the recombinant bgc . this characterization was performed through pcr assay using specific initiators , the same already described above and used to amplify and clone the ltk63 gene in the pmip12 vector ( fig1 ). to verify the expression of the ltak63 gene , the participants conducted an immunoassay ( western blot ) using a polyclonal anti - lt serum and taking the following steps : one or more stock aliquots of rbcg - ltak63 were sonicated for 1 . 5 min on ice at a constant amplitude corresponding to half the maximum value ( soniprep 150 mse , uk ) and centrifuged for precipitation of solids . the supernatants were recovered and the protein concentration dosed using the bio - rad protein assay ( bio - rad ) kit and employing bovine albumin as standard . samples containing 10 μg of total proteins were applied in 10 % polyacrylamide gel in presence of sodium dodecyl sulfate ( sds - page 1 . 0 %). electrophoresis was performed at room temperature at 120 v until the dye reached the end of the gel . after electrophoresis , the proteins were transferred to pdvf membrane with 0 . 45 μm pores ( ge healthcare ), using a semi - dry transfer system . the gel containing lt , as positive control , was glued on the pdvf membrane , immersed in transfer buffer ( tris 0 . 25 m tris , ph 8 . 3 , 0 . 129 m glycine and 20 % methanol ) and placed between five filter sheets also immersed in the same buffer . the set was placed between two plates and submitted to a current of 120 ma for 1 . 5 h at room temperature . at the end of the electrotransfer , the membrane was removed from the system and incubated in blocking solution ( pbs containing 5 % milk — milk / pbs ) at 4 ° c . overnight . at the end of the blocking , the membrane was incubated at room temperature for 2 h with serum anti - lt diluted in milk / pbs ( dilution 1 : 1000 ). after this incubation period , the pvdf membrane was washed three times under slight agitation , with 0 . 1 % pbs / tween20 ( pbs - t ) at 10 - min intervals . the membrane was then incubated for 2 h under the same conditions in milk / pbs containing hrp - conjugated anti - igg antibody ( sigma , chem co , st . louis ) and once again washed 3 times with pbs - t . the development was carried out by chemoluminescence using the ecl kit ( amersham ) through exposure in a photo documentation apparatus ( imagequant las4000 — ge ) ( fig2 ). humoral and cellular immune response assay of animals immunized with rbcg - ltk63 the study subjects were adult female balb / c mice ( mus musculus , rodentia , mammalia ) aged 6 - 8 weeks originating from and maintained under the standard conditions of the central animal facility of the school of medicine of the university of são paulo . bcg group : animals immunized subcutaneously ( s . c .) with 0 . 1 ml of bcg suspension ( 1 × 10 6 cfu / mouse suspended in pbs 1 ×); rbcg - ltk63 group : animals immunized subcutaneously ( s . c .) with 0 . 1 ml of rbcg - ltk63 suspension ( 1 × 10 6 cfu / mouse suspended in pbs 1 ×); rbcg - ltka63 group : animals immunized subcutaneously ( s . c .) with 0 . 1 ml of rbcg - ltak63 suspension ( 1 × 10 6 cfu / mouse suspended in pbs 1 ×); control group : animals inoculated with 0 . 1 ml of saline ( pbs 1 ×). a ) humoral response : for this procedure , the animals immunized or inoculated with the control , with bcg or rbcg - lt ( fig3 ) or with bcg or rbcg - ltak63 ( fig4 ), underwent retro - orbital bleeding one day before the challenge and had their serum separated and aliquoted for subsequent characterization by the elisa method . the isotypes were determined in serums isolated one day before the challenge against mtb or 90 days after immunization . the serums of 5 animals per group were analyzed individually by elisa , using specific mouse anti igg1 and igg2a antibodies . the humoral response analysis was conducted comparing the concentration of the antibodies and / or specific subtypes igg1 and igg2a against pds in the different immunization groups . the standard curve of these antibodies detected by specific monoclonal antibodies against the respective immunoglobulins was used for this purpose . the comparative analysis of the response of antibodies igg1 and igg2a induced against mycobacteria proteins ( pds ) is important , as it can provide data on the profile or behavior of the immune response against these proteins . emphasizing that a profile that shows a th1 - shifted response , and therefore more suitable for fighting an infection caused by mtb , can be identified through the igg1 / igg2a ratio ( fig3 and 4 ). b ) cellular response of rbcg - ltk63 : the evaluation of the cellular response of the saline , bcg and rbcg - ltk63 groups was carried out using the elisa and elispot methods . initially the spleens of the mice immunized as described above were removed 30 days after the first and only immunization , macerated and strained through screens with porosity of 70 μm ( cell strainer - bd falcon , bedford , mass .). the splenocytes thus obtained from each group ( saline , bcg and rbcg - ltk63 ) were counted in a neubauer chamber and had their viability assessed through trypan blue staining . cell dilution was then performed in rpmi complete medium [ rpmi 1610 ( gibco life technologies ), penicillin ( 100 u / ml ), streptomycin ( 100 μg / ml ) plus 10 % of bovine fetal serum ], in the concentration of 2 × 10 6 cells / ml in the elisa assay and 1 × 10 5 cells / ml in the elispot assay , followed by seeding on a 24 - well cell culture plate under pds stimulus ( 2 μg / ml ) and incubation for 24 hours and 48 hours , respectively , at 37 ° c . with 5 % co 2 atmosphere . in the group treated with rbcg - ltk63 a significant increase was observed in the levels of inf - γ and tnf - α in relation to the bcg group . this fact indicates a th1 polarized response ( fig5 and 6 ). c ) cellular response of rbcg - ltak63 the evaluation of the cellular response of the saline , bcg and rbcg - ltak63 groups was carried out using the elisa and flow cytometry ( facs ) methods . initially the spleens of the mice immunized as described above , were removed 60 days after the first and only immunization , macerated in pyrex tissue homogenizers ( fischer scientific — usa ) and had the splenocytes recovered . the splenocytes thus obtained from each group ( saline , bcg and rbcg - ltak63 ), were counted in a neubauer chamber and had their viability assessed through trypan blue staining . this stage was followed by cell dilution in rpmi complete medium [ rpmi 1640 ( gibco life technologies ), penicillin ( 100 u / ml ), streptomycin ( 100 μg / ml ) plus 10 % of bovine fetal serum ], in the concentration of 2 × 10 6 cells / ml for the elisa and facs assays . in the elisa assay the cells were seeded on a 24 - well cell culture plate under pds stimulus ( 2 μg / ml ) and incubated for 48 hours , at 37 ° c . with 5 % co 2 atmosphere . in the facs assay , a volume of 500 μl of cells was seeded on a 96 - well plate under pds stimulus ( 5 μg / ml ) and incubated for 5 hours at 37 ° c . with 5 % co 2 atmosphere . each sample was aliquoted and marked in three different tubes ( 200 μl / tube ) following protocol of intracellular permeabilization and marking to separately analyze the intracellular expression of inf - γ and tnf - α within the subpopulation of cd4 + t cells . a standard protocol provided by the manufacturer was used for the surface marking ( anti - cd4 - percp , bd pharmingen , san diego , calif . usa ) while the monoclonal ( mab ) anti - ifn - γ ( clone 4s . b3 ; ed pharmingen , san diego , calif ., usa ) and anti - tnf - α ( clone mab11 ; bd pharmingen , san diego , calif ., usa ) antibodies were used for intracellular marking . in the group treated with rbcg - ltak63 a significant increase was observed in the levels of inf - γ and tnf - α in relation to the bcg group , both in the elisa assays and in the flow cytometry assay . this fact indicates a th1 polarized response ( fig7 and 8 , elisa ; fig9 and 10 , facs ). development of the animal tuberculosis challenge model — assays of protection against an intratracheal challenge with the strain of tuberculosis h37rv the study subjects were adult female c57bl / 6 or balb / c mice ( mus musculus , rodentia , mammalia ) aged from 6 to 8 weeks and originating from and maintained under the standard conditions of the central animal facility of the school of medicine of the university of são paulo . the strain of mycobacterium tuberculosis ( mtb ) 37hrv was used for the challenge assays . this strain was cultured in mb7h9 / tw / adc liquid medium in an oven at 37 ° c . and 5 % co 2 . the bacillary suspension of mtb was cultured in mb7b9 / tw / adc medium for two weeks and only suspensions with at least 80 % of viable bacilli were used for the challenge by the intratracheal route . the bacillary culture was centrifuged at 4000 rpm and washed twice with an equal volume of the culture with pbs 1 ×. then the sediment was resuspended in 1 ml of pbs 1 × and the number of bacilli estimated using the macfarland scale . the intratracheal challenge followed the method previously described [ pelizon et al . ( 2010 ) neonatal bug immunization followed by dnahsp65 boosters : highly immunogenic but not protective against rodentia tuberculosis — a paradoxical effect of the vector ? scand j immunol . 71 : 63 - 69 . the mice were infected with 1 × 10 5 cpu of viable mtb or inoculated with 100 μl of pbs ( phosphate buffered saline ) via intratracheal route under anesthesia ( 200 μl of a mixture of ketamine / xylazine ). the animals were followed up for four weeks . after this period they were all sacrificed in a co 2 chamber and their lungs were removed for processing . one of the lobules of each lung was separated and macerated in a total volume of 1 ml of pbs 1 × solution . then this material was serially diluted and seeded in petri dishes containing mb7h10 / oadc solid medium . thirty days later , the number of cfu was determined in the plates corresponding to each group of immunized animals ( fig1 ).
the present invention relates to recombinant mycobacterium strain that encodes the mutated escherichia coli lt heat - labile toxin or the a subunit of the mutated escherichia coli lt heat - labile toxin . the present invention also relates to strains of mycobacterium that encode the lt heat - labile toxin or the a subunit of the lt heat - labile toxin of escherichia coli mutated in position 63 . specifically , the present invention relates to strains of mycobacterium that encode the lt heat - labile toxin or the a subunit of the lt heat - labile toxin of escherichia coli mutated in position 63 from serine to lysine . the present invention also provides immunogenic compositions that comprise the strains of the present invention . the present invention further provides for the use of said strains and immunological compositions in the production of a vaccine for preventing tuberculosis and infections caused by mycobacterium tuberculosis . lastly , the present invention relates to methods for preventing or treating tuberculosis in animals .